MISTMilestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a pr…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary Moby summary of Milestone Pharmaceuticals Inc.'s Q2 2026 earnings call | ||
 Milestone Pharmaceuticals Q2 Earnings Call Highlights Milestone Pharmaceuticals (NASDAQ:MIST) reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR. Chief Executive Officer Joseph Oliveto said CARDAMYST r | ||
 Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -16.67% and -30.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Milestone Pharmaceuticals shares tumble after Q2 earnings miss Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares dropped 12. | ||
 After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST) Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. | ||